[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"National Biological Corp\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":187},{"warningLetters":4,"total":186},[5,34,57,82,104,123,143,165],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":29,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":20,"reference_number":20,"action_taken_date":33,"medical_device_id":20,"response_letter_date":20},1988,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2023-07-18T13:20:00Z\">07\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-27T04:00:00Z\">06\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-06272023\">Edge Biologicals Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations Central ","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-02232026\">\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Walter C. Edge Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Edge Biologicals Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>635 North 3rd Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Memphis\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38107\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations Central \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 660003\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 27, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Edge:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Memphis, TN on March 20, 2023 through April 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class I and class II in vitro diagnostics (IVDs) for medical applications. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Walter C. Edge Jr, President, dated 04\u002F05\u002F2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations. The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>A). You failed to validate the cleaning process for controlled environmental areas used for the aseptic processing of Mueller Hinton Agar antimicrobial susceptibility test culture media and other culture media devices.\u003C\u002Fp>\n\n\u003Cp>B). You failed to validate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of tubing sets used in aseptic fill operations for culture media devices.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response does not ensure that processes whose results cannot be fully verified with subsequent inspection are validated.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish procedures for corrective and preventative actions, as required by 820.100(a). For example,\u003C\u002Fp>\n\n\u003Cp>A). You failed to analyze sources of quality data to identify existing and potential causes of nonconforming product or other quality problems. Analysis of quality data from 2019-2022 does not include data from product quality investigations, incoming inspection rejects, or audits as required by your procedure, QMS-005\u002FJ, Corrective and Preventive Action. Furthermore, your firm does not conduct analysis of environmental monitoring data for aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>B). Your firm failed to adequately investigate and identify actions needed to correct and prevent the recurrence of product sterility failures of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified on 04\u002F29\u002F2021 and Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified on 05\u002F07\u002F2021, as required by your procedure QA-008\u002FL, Product\u002FProcess Quality Incidents (PQI’s).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your response does not address requirements needed to ensure the causes of nonconformities relating to product, processes, and the quality system will be investigated, and actions will be taken to correct and prevent the recurrence.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish procedures and maintain requirements that must be met by suppliers, contractors, and consultants, as required by 820.50(a). For example, your firm purchases components and services critical to product quality; however, you failed to evaluate suppliers on their abilities to meet specific requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>4. Failure to maintain a device master record, as required by 21 CFR 820.181. For example, your firm failed to demonstrate that the Mueller Hinton Agar was manufactured according to the Device Master Record (DMR). Your quality manager could not locate the DMR to ensure the device production record (DHR) for each batch or lot of the Mueller Hinton Agar met specifications, including specifications for manufacturing, label requirements, and testing.\u003Cbr>\n\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). For example, your firm failed to implement the procedure 003-007, Environmental Monitoring, revised on 02\u002F26\u002F2021. Updates made to Attachment’s A, B, and H located within the procedure 003-007 were not implemented within the facility. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Mueller Hinton Agar, and other culture media is manufactured each day in controlled area which are not monitored as specified in your Environmental Monitoring procedure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80(a). You did not ensure that product is controlled until required acceptance activities have been completed and final release is authorized. In-process, nonconforming, and released IVD products were observed throughout production and storage areas without any indication of acceptance status. For example, testing media (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) was observed stored in the employee breakroom refrigerator with food items.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2015 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>7. Failure to conduct quality audits to determine whether the quality system activities and results comply with quality system procedures, as required by 21 CFR 820.22. From 2013 to 2019 your firm failed to conduct quality audits as required per QMS-003\u002FL, Quality System Internal Audit Program.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2018 inspection***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>8. Failure to ensure that personnel have necessary training and experience to perform their jobs, as required by 21 CFR 820.25(a). You failed to document adequate training as required by your procedure MAN-005\u002FI, EBI Employee Training. Five out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> production employees have no documented training records and no annual training on the quality system regulations has been documented for any employee.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>***This is a repeat observation cited during the 2015 and 2018 inspections***\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined where no documents were provided for review. Your firm’s response promised to implement corrective actions however the response was not comprehensive to address the systemic deficiencies identified including a corrective action plan and corrective actions to address the concerns along with timeframes to correct them.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Initial certifications by consultant and establishment – 12\u002F27\u002F2023\u003C\u002Fli>\n\t\u003Cli>Subsequent certifications – 12\u002F27\u002F2024 and 12\u002F27\u002F2025\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa I. Michurski, Director, Compliance Branch, via e-mail correspondence to ORADevices2FirmResponse@fda.hhs.gov. Refer to the Unique Identification Number (CMS Case # 660003) when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, via email at Ashley.mutawakkil@fda.hhs.gov or by phone at 305-816-1432.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological\u003Cbr>\nHealth\u003Cbr>\nDivision 2 – Central\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nWalter C. Edge Jr.\n\nRecipient Title\n\nPresident\n\nEdge Biologicals Inc.\n\n635 North 3rd Street\n\nMemphis, TN 38107\n\nUnited States\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations Central\n\nUnited States\n\nWARNING LETTER\n\nCMS# 660003\n\nJune 27, 2023\n\nDear Mr. Edge:\n\nDuring an inspection of your firm located in Memphis, TN on March 20, 2023 through April 4, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures class I and class II in vitro diagnostics (IVDs) for medical applications. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or are intended to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act (21 U.S.C. § 351(h)), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Walter C. Edge Jr, President, dated 04\u002F05\u002F2023, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations. The violations include, but are not limited to, the following:\n\n1. Failure to validate a process whose results cannot be fully verified by subsequent inspection and test according to established procedures, as required by 820.75(a). For example:\n\nA). You failed to validate the cleaning process for controlled environmental areas used for the aseptic processing of Mueller Hinton Agar antimicrobial susceptibility test culture media and other culture media devices.\n\nB). You failed to validate the (b)(4) sterilization of tubing sets used in aseptic fill operations for culture media devices.\n\n***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\n\nYour response does not ensure that processes whose results cannot be fully verified with subsequent inspection are validated.\n\n2. Failure to adequately establish procedures for corrective and preventative actions, as required by 820.100(a). For example,\n\nA). You failed to analyze sources of quality data to identify existing and potential causes of nonconforming product or other quality problems. Analysis of quality data from 2019-2022 does not include data from product quality investigations, incoming inspection rejects, or audits as required by your procedure, QMS-005\u002FJ, Corrective and Preventive Action. Furthermore, your firm does not conduct analysis of environmental monitoring data for aseptic processing operations.\n\nB). Your firm failed to adequately investigate and identify actions needed to correct and prevent the recurrence of product sterility failures of (b)(4), Lot (b)(4), identified on 04\u002F29\u002F2021 and Lot (b)(4), identified on 05\u002F07\u002F2021, as required by your procedure QA-008\u002FL, Product\u002FProcess Quality Incidents (PQI’s).\n\n***This is a repeated observation cited during the 2015 and 2018 inspections as well as the Warning Letter issued in 2012***\n\nYour response does not address requirements needed to ensure the causes of nonconformities relating to product, processes, and the quality system will be investigated, and actions will be taken to correct and prevent the recurrence.\n\n3. Failure to adequately establish procedures and maintain requirements that must be met by suppliers, contractors, and consultants, as required by 820.50(a). For example, your firm purchases components and services critical to product quality; however, you failed to evaluate suppliers on their abilities to meet specific requirements.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n4. Failure to maintain a device master record, as required by 21 CFR 820.181. For example, your firm failed to demonstrate that the Mueller Hinton Agar was manufactured according to the Device Master Record (DMR). Your quality manager could not locate the DMR to ensure the device production record (DHR) for each batch or lot of the Mueller Hinton Agar met specifications, including specifications for manufacturing, label requirements, and testing.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n5. Failure to adequately establish procedures to control environmental conditions, as required by 21 CFR 820.70(c). For example, your firm failed to implement the procedure 003-007, Environmental Monitoring, revised on 02\u002F26\u002F2021. Updates made to Attachment’s A, B, and H located within the procedure 003-007 were not implemented within the facility. (b)(4), Mueller Hinton Agar, and other culture media is manufactured each day in controlled area which are not monitored as specified in your Environmental Monitoring procedure.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n6. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80(a). You did not ensure that product is controlled until required acceptance activities have been completed and final release is authorized. In-process, nonconforming, and released IVD products were observed throughout production and storage areas without any indication of acceptance status. For example, testing media ((b)(4)) was observed stored in the employee breakroom refrigerator with food items.\n\n***This is a repeat observation cited during the 2015 inspection***\n\n7. Failure to conduct quality audits to determine whether the quality system activities and results comply with quality system procedures, as required by 21 CFR 820.22. From 2013 to 2019 your firm failed to conduct quality audits as required per QMS-003\u002FL, Quality System Internal Audit Program.\n\n***This is a repeat observation cited during the 2018 inspection***\n\n8. Failure to ensure that personnel have necessary training and experience to perform their jobs, as required by 21 CFR 820.25(a). You failed to document adequate training as required by your procedure MAN-005\u002FI, EBI Employee Training. Five out of (b)(4) production employees have no documented training records and no annual training on the quality system regulations has been documented for any employee.\n\n***This is a repeat observation cited during the 2015 and 2018 inspections***\n\nThe adequacy of your firm’s response cannot be determined where no documents were provided for review. Your firm’s response promised to implement corrective actions however the response was not comprehensive to address the systemic deficiencies identified including a corrective action plan and corrective actions to address the concerns along with timeframes to correct them.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\n\nInitial certifications by consultant and establishment – 12\u002F27\u002F2023\n\nSubsequent certifications – 12\u002F27\u002F2024 and 12\u002F27\u002F2025\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps you have taken to address the noted violations, as well as an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective action cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa I. Michurski, Director, Compliance Branch, via e-mail correspondence to ORADevices2FirmResponse@fda.hhs.gov. Refer to the Unique Identification Number (CMS Case # 660003) when replying. If you have any questions about the contents of this letter, please contact: Ashley Mutawakkil, Compliance Officer, via email at Ashley.mutawakkil@fda.hhs.gov or by phone at 305-816-1432.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and to bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBlake Bevill, MS\n\nProgram Division Director\n\nOffice of Medical Device and Radiological\n\nHealth\n\nDivision 2 – Central","Edge Biologicals Inc.","edge-biologicals-inc-660003-06272023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fedge-biologicals-inc-660003-06272023","2026-10-26T08:08:31.392911+00:00","Warning Letter","Closed Out","2023-07-18","660003","Medical Devices","2026-03-03","Division of Medical Device and Radiological Health Operations Central","Walter C. Edge Jr.","2026-08-20T00:52:33.091+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2023-06-27",{"id":35,"raw":36,"subject":41,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":19,"fei_number":20,"letter_url":47,"updated_at":48,"action_type":23,"case_status":24,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":52,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":20,"reference_number":20,"action_taken_date":56,"medical_device_id":20,"response_letter_date":20},1769,[37,38,39,40,41,13,42,13],"\u003Ctime datetime=\"2023-11-07T14:20:00Z\">11\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-04T04:00:00Z\">08\u002F04\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiorica-international-corp-659194-08042023\">Biorica International Corp.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiorica-international-corp-659194-04092024\">\u003Ctime datetime=\"2024-04-17T04:00:00Z\">04\u002F17\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jacqueline Baxas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Biorica International Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4310 Sheridan St., Suite 202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hollywood\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33021\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@biorica.biz\"> info@biorica.biz\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 4, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 659194\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jacqueline Baxas:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.plaquex.com\u002F, https:\u002F\u002Fbiorica.biz\u002Fen\u002F, https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F, and https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F in May 2023 and has determined that you take orders there for the product Plaquex® Oral Dietary Supplement. Your websites at https:\u002F\u002Fwww.plaquex.com\u002F and https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F direct customers to your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F, to purchase your product Plaquex® Oral Dietary Supplement. Your website https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F directs customers to your website https:\u002F\u002Fwww.plaquex.com\u002F, which then directs customers to your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F to purchase your product.\u003C\u002Fp>\n\n\u003Cp>The claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>On your website https:\u002F\u002Fwww.plaquex.com\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In 2006 Plaquex® Oral Gel Capsules were added to the treatment regimen. They improve blood lipids and liver and kidney function and thereby aid in the prevention of plaque deposits in between IV treatment sessions and after the infusion series is completed.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Plaquex Oral is indicated for lowering cholesterol levels, triglyceride levels and to improve liver function but also as a[n] additional treatment to Plaquex infusions to prevent re-formation of plaque in the blood vessels after removal. Plaquex Oral is also used in kidney disease as studies show that it increases creatinine and urea clearance in conjunction with Plaquex infusions. Studies in patients with Psoriasis and Neurodermitis show that skin manifestations recede faster and stay in remission longer than with placebo.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On your Facebook home page: “A revived treatment to prevent heart attack, stroke, amputations and other nasty things like liver a [sic]”\u003C\u002Fli>\n\t\u003Cli>In a July 31, 2017 post: “Can Plaquex® help prevent cancer?...Conclusion…In conclusion we can surmise that supplying phospholipids of the kind used in Plaquex® improves cell membrane function including the function of Sodium-potassium ATPase, and thus helps to maintain negative voltage in the cell preventing dedifferentiation of the cell into cancer cells. As the title says, this is only a thought experiment. Retrospective studies need to be done with patients doing Plaquex® therapy over a long period of time and comparing their rate of new cancers to the rate of a matched control group.”\u003C\u002Fli>\n\t\u003Cli>In a July 29, 2017 post: “Can Plaquex® help prevent cancer?...When I linked the facts of these three independent information sources, the thought came to me, that Plaquex® – Phosphatidylcholine – may be able to prevent cancer.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>In a August 19, 2016 post: “Stop buying lecithin and generic phosphatidylcholine products. Most will do more harm than good and actually increase plaque build-up in your arteries and cause fatty liver disease…You can help your body heal itself. Plaquex® Oral is a beautiful way to do just that…Imagine visiting your doctor one day as he smiles and says “Your cholesterol is back to normal!”…Plaquex® Oral can give you all this and more.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Plaquex® Oral Dietary Supplement is not generally recognized as safe and effective for the above referenced uses and, therefore, it is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003Cbr>\n\u003Cbr>\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Plaquex® Oral Dietary Supplement is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Plaquex® Oral Dietary Supplement fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the United States Food and Drug Administration at CFSANResponse@fda.hhs.gov. Please include “CMS 659194” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJacqueline Baxas\n\nRecipient Title\n\nPresident\n\nBiorica International Corp.\n\n4310 Sheridan St., Suite 202\n\nHollywood, FL 33021\n\nUnited States\n\ninfo@biorica.biz\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nAugust 4, 2023\n\nRE: 659194\n\nDear Jacqueline Baxas:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.plaquex.com\u002F, https:\u002F\u002Fbiorica.biz\u002Fen\u002F, https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F, and https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F in May 2023 and has determined that you take orders there for the product Plaquex® Oral Dietary Supplement. Your websites at https:\u002F\u002Fwww.plaquex.com\u002F and https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F direct customers to your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F, to purchase your product Plaquex® Oral Dietary Supplement. Your website https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F directs customers to your website https:\u002F\u002Fwww.plaquex.com\u002F, which then directs customers to your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F to purchase your product.\n\nThe claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\nOn your website https:\u002F\u002Fwww.plaquex.com\u002F:\n\n“In 2006 Plaquex® Oral Gel Capsules were added to the treatment regimen. They improve blood lipids and liver and kidney function and thereby aid in the prevention of plaque deposits in between IV treatment sessions and after the infusion series is completed.”\n\nOn your website https:\u002F\u002Fbiorica.biz\u002Fen\u002F:\n\n“Plaquex Oral is indicated for lowering cholesterol levels, triglyceride levels and to improve liver function but also as a[n] additional treatment to Plaquex infusions to prevent re-formation of plaque in the blood vessels after removal. Plaquex Oral is also used in kidney disease as studies show that it increases creatinine and urea clearance in conjunction with Plaquex infusions. Studies in patients with Psoriasis and Neurodermitis show that skin manifestations recede faster and stay in remission longer than with placebo.”\n\nOn your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002Fpeople\u002FPlaquex\u002F100063669775556\u002F:\n\nOn your Facebook home page: “A revived treatment to prevent heart attack, stroke, amputations and other nasty things like liver a [sic]”\n\nIn a July 31, 2017 post: “Can Plaquex® help prevent cancer?...Conclusion…In conclusion we can surmise that supplying phospholipids of the kind used in Plaquex® improves cell membrane function including the function of Sodium-potassium ATPase, and thus helps to maintain negative voltage in the cell preventing dedifferentiation of the cell into cancer cells. As the title says, this is only a thought experiment. Retrospective studies need to be done with patients doing Plaquex® therapy over a long period of time and comparing their rate of new cancers to the rate of a matched control group.”\n\nIn a July 29, 2017 post: “Can Plaquex® help prevent cancer?...When I linked the facts of these three independent information sources, the thought came to me, that Plaquex® – Phosphatidylcholine – may be able to prevent cancer.”\n\nOn your Facebook social media website at https:\u002F\u002Fwww.facebook.com\u002Fwww.biorica.biz\u002F:\n\nIn a August 19, 2016 post: “Stop buying lecithin and generic phosphatidylcholine products. Most will do more harm than good and actually increase plaque build-up in your arteries and cause fatty liver disease…You can help your body heal itself. Plaquex® Oral is a beautiful way to do just that…Imagine visiting your doctor one day as he smiles and says “Your cholesterol is back to normal!”…Plaquex® Oral can give you all this and more.”\n\nYour Plaquex® Oral Dietary Supplement is not generally recognized as safe and effective for the above referenced uses and, therefore, it is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Plaquex® Oral Dietary Supplement is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Plaquex® Oral Dietary Supplement fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the United States Food and Drug Administration at CFSANResponse@fda.hhs.gov. Please include “CMS 659194” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration","Biorica International Corp.","biorica-international-corp-659194-08042023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiorica-international-corp-659194-08042023","2026-10-26T08:08:05.433123+00:00","2023-11-07","659194","Dietary SupplementsFood & Beverages","2024-04-17","Jacqueline Baxas","2026-08-20T00:33:15.127+00:00","Via Overnight Delivery","2023-08-04",{"id":58,"raw":59,"subject":65,"body_html":66,"body_text":67,"firm_name":68,"letter_id":69,"created_at":70,"fei_number":20,"letter_url":71,"updated_at":72,"action_type":23,"case_status":73,"posted_date":74,"marcs_cms_no":75,"product_type":76,"closeout_date":20,"issuing_office":63,"recipient_name":77,"body_fetched_at":78,"delivery_method":79,"recipient_title":20,"reference_number":80,"action_taken_date":81,"medical_device_id":20,"response_letter_date":20},1077,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-30T05:00:00Z\">12\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024\">Evolutionary Biologics Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-681586\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Morrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evolutionary Biologics Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Penn Plaza West 34th Street Floor 9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@evolutionarybiologics.com\"> admin@evolutionarybiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 30, 2024\u003C\u002Fp>\u003Cp>Warning Letter #: CBER-24-681586\u003C\u002Fp>\u003Cp>Dear Mr. Morrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\u003C\u002Fp>\u003Cp>\u003Cu>EVO JEL™\u003C\u002Fu>\u003Cbr>• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\u003Cbr>• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\u003Cbr>• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder &amp; Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\u003C\u002Fp>\u003Cp>\u003Cu>EVO HYBRID™\u003C\u002Fu>\u003Cbr>• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\u003Cbr>• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\u003Cbr>&nbsp; &nbsp; • “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 &amp; 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\u003Cbr>&nbsp; &nbsp; • IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\u003Cbr>&nbsp; &nbsp; • B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\u003C\u002Fp>\u003Cp>\u003Cu>EXO RNA™\u003C\u002Fu>\u003Cbr>• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”&nbsp;&nbsp;\u003Cbr>• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\u003Cbr>&nbsp; &nbsp; • TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\u003C\u002Fp>\u003Cp>Based on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>In addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>Additionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>Therefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&amp;C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&amp;C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&amp;C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&amp;C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In addition, we have concerns with your products EXO RX, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong>, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\u003Cbr>• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\u003Cbr>• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\u003Cbr>• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\u003Cbr>• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”&nbsp;\u003Cbr>• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\u003Cbr>• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\u003C\u002Fp>\u003Cp>FDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong> products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\u003C\u002Fp>\u003Cp>Your response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>Melissa J. Mendoza\u003Cbr>Director, Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER-24-681586\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJim Morrison\n\nRecipient Title\n\nCEO\n\nEvolutionary Biologics Inc.\n\n14 Penn Plaza West 34th Street Floor 9\n\nNew York, NY 10122\n\nUnited States\n\nadmin@evolutionarybiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nDecember 30, 2024\nWarning Letter #: CBER-24-681586\nDear Mr. Morrison:\nThe United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\nEVO JEL™\n• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\n• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\n• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder & Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\nEVO HYBRID™\n• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\n• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\n• “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 & 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\n• IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\n• B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\nEXO RNA™\n• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”\n• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\n• TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\nYour product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\nBased on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\nFor example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\nIn addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nAdditionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.1\nIn addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\nTherefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\nIn addition, we have concerns with your products EXO RX, EXO ELIXIR™ and EXO PERIO™, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\n• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\n• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\n• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\n• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”\n• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\n• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\nFDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and EXO PERIO™ products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nYour response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\nMelissa J. Mendoza\nDirector, Office of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n______________________\n1 You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\n2 Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Evolutionary Biologics Inc.","evolutionary-biologics-inc-681586-12302024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024","2026-10-26T08:08:37.862855+00:00","Issued","2025-01-28","681586","Biologics","Jim Morrison","2026-08-19T17:03:23.375+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","CBER-24-681586","2024-12-30",{"id":83,"raw":84,"subject":89,"body_html":90,"body_text":91,"firm_name":92,"letter_id":93,"created_at":94,"fei_number":20,"letter_url":95,"updated_at":96,"action_type":23,"case_status":73,"posted_date":97,"marcs_cms_no":98,"product_type":99,"closeout_date":20,"issuing_office":88,"recipient_name":100,"body_fetched_at":101,"delivery_method":102,"recipient_title":20,"reference_number":20,"action_taken_date":103,"medical_device_id":20,"response_letter_date":20},21683,[85,86,87,88,89,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesbiodeseret-biologicals-inc-735464-10012026\">DesBio\u002FDeseret Biologicals, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jake Carter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DesBio\u002FDeseret Biologicals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>469 West Parkland Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sandy\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:practitionersupport@desbio.com\"> practitionersupport@desbio.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 735464\u003C\u002Fp>\u003Cp>To Jake Carter:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fdesbio.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fdesbio.com\u002F in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “CHLA:10M” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003Cbr>On the product label:\u003C\u002Fp>\u003Cul>\u003Cli>“Chlamydia 10M”\u003C\u002Fli>\u003Cli>“Chlamydia trachomatis 10M . . . Burning Sensation During Urination, Testicular Tenderness or Pain, Vaginal Discharge, Painful Sexual Intercourse”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the webpage https:\u002F\u002Fdesbio.com\u002Fproduct\u002Fchlamydia-series-symptom-relief-series-kit-10m\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“chlamydia, series symptom relief”\u003C\u002Fli>\u003Cli>“CHLA:10M is for the temporary relief of symptoms related to Chlamydia infection. Male: burning sensation during urination and testicular tenderness or pain. Female: vaginal discharge, burning sensation during urination, and painful sexual intercourse.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“CHLA:10M” is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this product.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735464” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cstrong>1\u003C\u002Fstrong> We recognize that the “CHLA:10M” labeling describes the product as being “homeopathic.”\u003C\u002Fp>\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product contains Chlamydia trachomatis 10M which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\u003C\u002Fp>\u003Cp>Notwithstanding, even if your above listed product is considered “homeopathic drug product\" under this guidance, the product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJake Carter\n\nRecipient Title\n\nChief Executive Officer\n\nDesBio\u002FDeseret Biologicals, Inc.\n\n469 West Parkland Drive\n\nSandy, UT 84070\n\nUnited States\n\npractitionersupport@desbio.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 735464\nTo Jake Carter:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fdesbio.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “CHLA:10M” product available for purchase on your website is an unapproved new drug. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fdesbio.com\u002F in July 2026. Based on our review, “CHLA:10M” is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “CHLA:10M” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nOn the product label:\n“Chlamydia 10M”\n“Chlamydia trachomatis 10M . . . Burning Sensation During Urination, Testicular Tenderness or Pain, Vaginal Discharge, Painful Sexual Intercourse”\nOn the webpage https:\u002F\u002Fdesbio.com\u002Fproduct\u002Fchlamydia-series-symptom-relief-series-kit-10m\u002F:\n“chlamydia, series symptom relief”\n“CHLA:10M is for the temporary relief of symptoms related to Chlamydia infection. Male: burning sensation during urination and testicular tenderness or pain. Female: vaginal discharge, burning sensation during urination, and painful sexual intercourse.”\n“CHLA:10M” is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this product.1 Accordingly, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “735464” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________________\n1 We recognize that the “CHLA:10M” labeling describes the product as being “homeopathic.”\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product contains Chlamydia trachomatis 10M which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\nNotwithstanding, even if your above listed product is considered “homeopathic drug product\" under this guidance, the product would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","DesBio\u002FDeseret Biologicals, Inc.","desbiodeseret-biologicals-inc-735464-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdesbiodeseret-biologicals-inc-735464-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","735464","Drugs Over-the-Counter Drugs","Jake Carter","2026-10-14T12:33:01.458+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-01",{"id":105,"raw":106,"subject":12,"body_html":111,"body_text":112,"firm_name":113,"letter_id":114,"created_at":70,"fei_number":20,"letter_url":115,"updated_at":116,"action_type":23,"case_status":73,"posted_date":117,"marcs_cms_no":118,"product_type":27,"closeout_date":20,"issuing_office":119,"recipient_name":120,"body_fetched_at":121,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":122,"medical_device_id":20,"response_letter_date":20},1474,[107,108,109,110,12,13,13,13],"\u003Ctime datetime=\"2024-05-07T13:20:00Z\">05\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-03T04:00:00Z\">04\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbioptimal-international-678281-04032024\">Bioptimal International\u003C\u002Fa>","&quot;OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality&quot;","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lai Chunhong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bioptimal International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3A, Unit 1, Building F, Tianebao (Stage Two), No. 2, Xiangshan Middle Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanshan Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 678281\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 3, 2024\u003Cbr>\n\u003Cbr>\nDear Ms. Chunhong:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Singapore, Southwest on November 6, 2023 through November 11, 2023 an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Thermodilution Catheter and Pulmonary Artery Monitoring Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter is a correction to the letter issued on April 3, 2024. It communicates identical issues but utilizes the FDA letterhead.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You currently have a clearance for the 'Thermodilution Catheter under K101669. Our inspection revealed that your firm made changes to the materials of the cleared device, including removal of the polyvinylchloride (PVC) tubing heparin coating, without submission of a new 510(k) premarket notification. This change could significantly affect the safety or effectiveness of the device and requires the submission of a new 510(k) premarket notification 21 CFR 807.81(a)(3)(i). For example, removal of this coating can increase friction in the tubing and negatively impact the thrombogenicity profile of the device.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> This can lead to increased blood clotting and\u002For thrombus, which can result in embolization during clinical use, significantly impacting patient safety.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm is marketing a Pulmonary Artery Catheter and claiming this device maintains the same device design as the cleared Thermodilution Catheter (K101669). However, based on the information gathered during the inspection, it appears the Pulmonary Artery Catheter has several technological characteristics that differ from the cleared Thermodilution Catheter. The 510(k) Summary for the Thermodilution catheter states that the device maintains a 4- and 5-lumen design with the extension and includes a thermistor. The Pulmonary Catheter is noted to include a 2- and 3-lumen configuration and does not maintain a thermistor element. Modification to the lumen design and removal of the thermistor change structural device properties and the ability to perform functions such as providing accurate measurements of body temperature during clinical use. Without proper evaluation to demonstrate the device continues to perform to appropriate standards, there is a higher risk of device failure during use, which can significantly impact patient safety. Considering this, a submission of a new 510(k) premarket notification is required according to 21 CFR 807.81(a)(3)(i).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Accordingly, both the Thermodilution Catheter and the Pulmonary Artery Monitoring Catheter devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for either device. The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 30, 2023, concerning our investigator's observations noted on the Form FDA 483, List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a) and (d). For example:\u003C\u002Fp>\n\n\u003Cp>The complaint handling procedure, BQS-005, does not require that any incoming complaint be evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803, Medical Device Reporting (MDR). Further, your firm did not review, evaluate, and investigate certain complaints in a timely manner to determine whether they represent an event which must be reported to FDA under 21 CFR part 803, and such complaints did not include the appropriate records including the name of the device, the date the complaint was received, the Unique Device Identifier (UDI), and the name, address, and phone number of the complainant. We also note that your firm's complaint handling procedures do not require that complaint investigation records include the required information above.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time because your corrective actions are not yet complete. In your response you state your planned corrective action includes a retrospective review of adverse events to determine MDR reportability, including completeness of adverse event report records, and revision of complaint record procedure to ensure UDI compliance. You stated your corrective actions will be completed by February and March of 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your complaint record procedure and any associated evidence of the corrective actions.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), specifically, verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\n\n\u003Cp>Some procedures of your firm's corrective and preventive actions, BQS-004 and BQS-005, have not been clearly established and your firm is not consistent with compliance\u002Ffollow-through when it initiates corrective actions. Specifically, your firm has not demonstrated consistent collection of evidence of the completion of previous corrective actions, and your firm lacks procedures for verification or validation of effectiveness conducted after corrective action. In addition, there have been instances where quality data sources indicated data trends, including two or more complaints from the same lot reporting similar failure modes and\u002For device malfunctioning, which were not investigated further (i.e., no corrective action was taken even though the complaint handling documents required otherwise). Lastly, your firm failed to take corrective action when the actual occurrence rates of several device failure modes exceeded the anticipated occurrence rates specified in the risk management file for the Thermodilution Catheter.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response, you state your planned corrective action plan includes updating current CAPA procedures to include new device risk assessments and escalating all complaints from different SOP sources. In addition, you plan to initiate CAPAs for current customer complaints to provide resolution retrospectively. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the newly updated CAPA procedures and details\u002Fstrategy for initiating CAPAs for current customer complaints.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to validate device design to ensure that devices conform to defined user needs and intended uses, and include risk analysis where appropriate, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's risk analysis procedures are inadequate. The actual occurrence rate of several device failure modes exceeded the anticipated occurrence rates that were specified in the risk management file and your firm did not take appropriate action. Further, your firm's risk analysis plan, BQS-006, specifies that the risk management file be reviewed and updated annually following an analysis of risks related to customer complaints and other items. The main device under consideration for repeated device failure is the Thermodilution Catheter and accessories. The failures include balloon rupture, balloon deflation difficulty, balloon inflation problems, pressure measurement issue, and cardiac output measurement issue. A device change was made to remove the heparin coating from the catheter shaft of the tubing and there was not documented assessment of the impact of friction resistance related to this change.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response you state your planned corrective action includes updating the risk assessment report for the Thermodilution Catheter, Pulmonary Artery Catheter, and Biotray to account for the number of device failures. In addition, you state that friction resistance testing will be conducted using non-coated tubing materials for the Thermodilution Catheter. You state your corrective actions will be completed by March 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide your updated documentation including, but not limited to, the revised versions of your risk management file with updated device failures for your devices. Please refer to the \"Unapproved Device Violation\" section above and provide the friction resistance testing as part of a new 510(k) premarket notification.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm has not established procedures to conduct sterilization process validation. Without these procedures, your firm has not specified requirements to validate sterilization processes, instructions on testing frequency, and instructions for requalification of sterilization activities. Your firm also does not have a set plan for monitoring and controlling process parameters to ensure that sterilization specifications are met.\u003C\u002Fp>\n\n\u003Cp>Your response dated November 30, 2023, does not completely address this observation. In your response you state your planned corrective action includes establishing and creating a sterilization process validation procedure according to the current practice and sterilization method employed. You also plan to send the new QA staff for process validation concepts and awareness external training. You state your corrective actions will be completed by January 2024, but FDA has not received this information by the date of this letter. In your response to this Warning letter, you should provide updated documentation including, but not limited to, the revised versions of your sterilization validation procedure and QA staff training certification. Further, your response is not adequate because you have not indicated that you will perform validation where appropriate to determine whether action is needed for product already distributed under these procedures.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain device history record (DHR) procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184(e) and (f). For example:\u003C\u002Fp>\n\n\u003Cp>Your firm has not established complete procedures to track device history records (DHR). Specifically, the currently established DHRs do not include or refer to where information regarding the primary identification label for each product unit and the unique device identifier can be found.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time as your corrective actions are not yet complete. In your response you state your planned corrective actions include revision and updating of the DHR work instruction to include the CFR reporting requirements and primary packaging label with the UDI. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In your response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your DHR work instruction and updated primary packaging labels with the device UDI.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Reporting Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm's Thermodilution Catheter device is misbranded under section 502(0(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the document titled \"Vigilance reporting and recalls\u002FFSCA for USFDA\", BPI-WI-010, Rev. 01, dated 10\u002F26\u002F2023 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a) The procedure includes the definition from 21 CFR 803.3 for the terms \"MDR reportable event\", \"become aware\", \"caused or contributed\", \"malfunction\", and \"serious injury\". However, the procedure does not provide clear guidance to staff on how they should determine if information \"reasonably suggests\" that an event should be reported. Refer to the definition of the term \"reasonably suggests\" found in 21 CFR 803.20(c)(1). The exclusion of such information from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>b) The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\u003C\u002Fp>\n\n\u003Cp>c) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include a process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive.\u003C\u002Fp>\n\n\u003Cp>d) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\n&nbsp; a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\n&nbsp; b. Information that was evaluated to determine if an event was reportable.\u003Cbr>\n&nbsp; c. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time. In the response, your firm outlined a plan to address each identified deficiency, including projected completion dates. However, as these corrective actions are still in progress, there is no documentation or evidence available yet to confirm their completion.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>The information included for Complaint CCS23-04-025 reasonably suggests that a patient sustained an injury that resulted in a thrombus, after a procedure using your firm's Central Venous Catheter. This condition necessitated drug treatment. In the absence of the information indicating the contrary, we believe that the drug treatment was necessitated to prevent permanent impairment of a body function or damage to a body structure. Therefore, the information included in the complaint reasonably suggests a serious injury for which an MDR must be submitted. Your firm became aware of this event on March 24, 2023. However, an MDR for the corresponding event has not yet been received by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm's response dated November 30, 2023, did not address the noted violation as the issue was not included in the FDA Form 483. In response to this Warning Letter, you should provide documentation to address this identified violation.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent by email to CDRHWarningLetterResponsesafda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case #678281 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: Lydia S. Glaw, Ph.D. at 301-796-1456.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman\u003Cbr>\nDr. Bram Zuckerman\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nDennis Bassett\u003Cbr>\nBIOMEDICAL SALES INTERNATIONAL, INC.\u003Cbr>\n457 W Virginia Ave\u003Cbr>\nPunta Gorda, FL US 33950\u003Cbr>\nPhone: 513 2586555 Ext\u003Cbr>\nFax: 513 7728388\u003Cbr>\nEmail: Dwbassett@Cs.Com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In October 2017, FDA published the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device (\"510(k) Modifications Guidance\"), which provided FDA's current thinking to enhance the predictability, consistency, and transparency of the when a change in a medical device would trigger the requirement that a manufacturer submit a new 510(k) premarket notification to the Agency. \u003Cem>Available\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatorv-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device. As explained in Section C.4.1 of the guidance, in general, changing the material or device design may affect the performance testing of the device.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained in Section B.5 of the 510(k) Modification Guidance, in general, changing the device design (e.g., dimensional and component changes) may result in new technological characteristics that raise different questions of safety and effectiveness.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Lai Chunhong\n\nRecipient Title\n\nGroup CEO\n\nBioptimal International\n\n3A, Unit 1, Building F, Tianebao (Stage Two), No. 2, Xiangshan Middle Street\n\nNanshan Qu\n\nShenzhen Shi\n\nGuangdong Sheng,\n\nChina\n\nIssuing Office:\n\n\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nWARNING LETTER\n\nCMS # 678281\n\nApril 3, 2024\n\nDear Ms. Chunhong:\n\nDuring an inspection of your firm located in Singapore, Southwest on November 6, 2023 through November 11, 2023 an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Thermodilution Catheter and Pulmonary Artery Monitoring Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter is a correction to the letter issued on April 3, 2024. It communicates identical issues but utilizes the FDA letterhead.\n\nUnapproved Device Violation\n\nYou currently have a clearance for the 'Thermodilution Catheter under K101669. Our inspection revealed that your firm made changes to the materials of the cleared device, including removal of the polyvinylchloride (PVC) tubing heparin coating, without submission of a new 510(k) premarket notification. This change could significantly affect the safety or effectiveness of the device and requires the submission of a new 510(k) premarket notification 21 CFR 807.81(a)(3)(i). For example, removal of this coating can increase friction in the tubing and negatively impact the thrombogenicity profile of the device.1 This can lead to increased blood clotting and\u002For thrombus, which can result in embolization during clinical use, significantly impacting patient safety.\n\nOur inspection also revealed that your firm is marketing a Pulmonary Artery Catheter and claiming this device maintains the same device design as the cleared Thermodilution Catheter (K101669). However, based on the information gathered during the inspection, it appears the Pulmonary Artery Catheter has several technological characteristics that differ from the cleared Thermodilution Catheter. The 510(k) Summary for the Thermodilution catheter states that the device maintains a 4- and 5-lumen design with the extension and includes a thermistor. The Pulmonary Catheter is noted to include a 2- and 3-lumen configuration and does not maintain a thermistor element. Modification to the lumen design and removal of the thermistor change structural device properties and the ability to perform functions such as providing accurate measurements of body temperature during clinical use. Without proper evaluation to demonstrate the device continues to perform to appropriate standards, there is a higher risk of device failure during use, which can significantly impact patient safety. Considering this, a submission of a new 510(k) premarket notification is required according to 21 CFR 807.81(a)(3)(i).2\n\nAccordingly, both the Thermodilution Catheter and the Pulmonary Artery Monitoring Catheter devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for either device. The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\n\nQuality System Violations\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 30, 2023, concerning our investigator's observations noted on the Form FDA 483, List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a) and (d). For example:\n\nThe complaint handling procedure, BQS-005, does not require that any incoming complaint be evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803, Medical Device Reporting (MDR). Further, your firm did not review, evaluate, and investigate certain complaints in a timely manner to determine whether they represent an event which must be reported to FDA under 21 CFR part 803, and such complaints did not include the appropriate records including the name of the device, the date the complaint was received, the Unique Device Identifier (UDI), and the name, address, and phone number of the complainant. We also note that your firm's complaint handling procedures do not require that complaint investigation records include the required information above.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time because your corrective actions are not yet complete. In your response you state your planned corrective action includes a retrospective review of adverse events to determine MDR reportability, including completeness of adverse event report records, and revision of complaint record procedure to ensure UDI compliance. You stated your corrective actions will be completed by February and March of 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your complaint record procedure and any associated evidence of the corrective actions.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), specifically, verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a). For example:\n\nSome procedures of your firm's corrective and preventive actions, BQS-004 and BQS-005, have not been clearly established and your firm is not consistent with compliance\u002Ffollow-through when it initiates corrective actions. Specifically, your firm has not demonstrated consistent collection of evidence of the completion of previous corrective actions, and your firm lacks procedures for verification or validation of effectiveness conducted after corrective action. In addition, there have been instances where quality data sources indicated data trends, including two or more complaints from the same lot reporting similar failure modes and\u002For device malfunctioning, which were not investigated further (i.e., no corrective action was taken even though the complaint handling documents required otherwise). Lastly, your firm failed to take corrective action when the actual occurrence rates of several device failure modes exceeded the anticipated occurrence rates specified in the risk management file for the Thermodilution Catheter.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response, you state your planned corrective action plan includes updating current CAPA procedures to include new device risk assessments and escalating all complaints from different SOP sources. In addition, you plan to initiate CAPAs for current customer complaints to provide resolution retrospectively. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the newly updated CAPA procedures and details\u002Fstrategy for initiating CAPAs for current customer complaints.\n\n3. Failure to establish and maintain procedures to validate device design to ensure that devices conform to defined user needs and intended uses, and include risk analysis where appropriate, as required by 21 CFR 820.30(g). For example:\n\nYour firm's risk analysis procedures are inadequate. The actual occurrence rate of several device failure modes exceeded the anticipated occurrence rates that were specified in the risk management file and your firm did not take appropriate action. Further, your firm's risk analysis plan, BQS-006, specifies that the risk management file be reviewed and updated annually following an analysis of risks related to customer complaints and other items. The main device under consideration for repeated device failure is the Thermodilution Catheter and accessories. The failures include balloon rupture, balloon deflation difficulty, balloon inflation problems, pressure measurement issue, and cardiac output measurement issue. A device change was made to remove the heparin coating from the catheter shaft of the tubing and there was not documented assessment of the impact of friction resistance related to this change.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response you state your planned corrective action includes updating the risk assessment report for the Thermodilution Catheter, Pulmonary Artery Catheter, and Biotray to account for the number of device failures. In addition, you state that friction resistance testing will be conducted using non-coated tubing materials for the Thermodilution Catheter. You state your corrective actions will be completed by March 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide your updated documentation including, but not limited to, the revised versions of your risk management file with updated device failures for your devices. Please refer to the \"Unapproved Device Violation\" section above and provide the friction resistance testing as part of a new 510(k) premarket notification.\n\n4. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75. For example:\n\nYour firm has not established procedures to conduct sterilization process validation. Without these procedures, your firm has not specified requirements to validate sterilization processes, instructions on testing frequency, and instructions for requalification of sterilization activities. Your firm also does not have a set plan for monitoring and controlling process parameters to ensure that sterilization specifications are met.\n\nYour response dated November 30, 2023, does not completely address this observation. In your response you state your planned corrective action includes establishing and creating a sterilization process validation procedure according to the current practice and sterilization method employed. You also plan to send the new QA staff for process validation concepts and awareness external training. You state your corrective actions will be completed by January 2024, but FDA has not received this information by the date of this letter. In your response to this Warning letter, you should provide updated documentation including, but not limited to, the revised versions of your sterilization validation procedure and QA staff training certification. Further, your response is not adequate because you have not indicated that you will perform validation where appropriate to determine whether action is needed for product already distributed under these procedures.\n\n5. Failure to establish and maintain device history record (DHR) procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184(e) and (f). For example:\n\nYour firm has not established complete procedures to track device history records (DHR). Specifically, the currently established DHRs do not include or refer to where information regarding the primary identification label for each product unit and the unique device identifier can be found.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time as your corrective actions are not yet complete. In your response you state your planned corrective actions include revision and updating of the DHR work instruction to include the CFR reporting requirements and primary packaging label with the UDI. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In your response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your DHR work instruction and updated primary packaging labels with the device UDI.\n\nMedical Device Reporting Violation\n\nOur inspection also revealed that your firm's Thermodilution Catheter device is misbranded under section 502(0(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the document titled \"Vigilance reporting and recalls\u002FFSCA for USFDA\", BPI-WI-010, Rev. 01, dated 10\u002F26\u002F2023 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na) The procedure includes the definition from 21 CFR 803.3 for the terms \"MDR reportable event\", \"become aware\", \"caused or contributed\", \"malfunction\", and \"serious injury\". However, the procedure does not provide clear guidance to staff on how they should determine if information \"reasonably suggests\" that an event should be reported. Refer to the definition of the term \"reasonably suggests\" found in 21 CFR 803.20(c)(1). The exclusion of such information from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb) The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\n\nc) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include a process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive.\n\nd) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time. In the response, your firm outlined a plan to address each identified deficiency, including projected completion dates. However, as these corrective actions are still in progress, there is no documentation or evidence available yet to confirm their completion.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\n\nThe information included for Complaint CCS23-04-025 reasonably suggests that a patient sustained an injury that resulted in a thrombus, after a procedure using your firm's Central Venous Catheter. This condition necessitated drug treatment. In the absence of the information indicating the contrary, we believe that the drug treatment was necessitated to prevent permanent impairment of a body function or damage to a body structure. Therefore, the information included in the complaint reasonably suggests a serious injury for which an MDR must be submitted. Your firm became aware of this event on March 24, 2023. However, an MDR for the corresponding event has not yet been received by FDA.\n\nYour firm's response dated November 30, 2023, did not address the noted violation as the issue was not included in the FDA Form 483. In response to this Warning Letter, you should provide documentation to address this identified violation.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent by email to CDRHWarningLetterResponsesafda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #678281 when replying. If you have any questions about the contents of this letter, please contact: Lydia S. Glaw, Ph.D. at 301-796-1456.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman\n\nDr. Bram Zuckerman\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nDennis Bassett\n\nBIOMEDICAL SALES INTERNATIONAL, INC.\n\n457 W Virginia Ave\n\nPunta Gorda, FL US 33950\n\nPhone: 513 2586555 Ext\n\nFax: 513 7728388\n\nEmail: Dwbassett@Cs.Com\n\n______________________\n\n1 In October 2017, FDA published the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device (\"510(k) Modifications Guidance\"), which provided FDA's current thinking to enhance the predictability, consistency, and transparency of the when a change in a medical device would trigger the requirement that a manufacturer submit a new 510(k) premarket notification to the Agency. Available at https:\u002F\u002Fwww.fda.gov\u002Fregulatorv-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device. As explained in Section C.4.1 of the guidance, in general, changing the material or device design may affect the performance testing of the device.\n\n2 As explained in Section B.5 of the 510(k) Modification Guidance, in general, changing the device design (e.g., dimensional and component changes) may result in new technological characteristics that raise different questions of safety and effectiveness.","Bioptimal International","bioptimal-international-678281-04032024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbioptimal-international-678281-04032024","2026-10-26T08:08:05.402825+00:00","2024-05-07","678281","\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"","Ms. Lai Chunhong","2026-08-20T00:06:56.589+00:00","2024-04-03",{"id":124,"raw":125,"subject":65,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":133,"fei_number":20,"letter_url":134,"updated_at":135,"action_type":23,"case_status":73,"posted_date":136,"marcs_cms_no":137,"product_type":76,"closeout_date":20,"issuing_office":63,"recipient_name":138,"body_fetched_at":139,"delivery_method":140,"recipient_title":20,"reference_number":141,"action_taken_date":142,"medical_device_id":20,"response_letter_date":20},696,[126,127,128,63,64,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-15T04:00:00Z\">08\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025\">Platinum Biologics LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-705090\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Beeben Russell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman of the Board \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Platinum Biologics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1510 E Colonial Drive, Suite 103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@platinumbiologics.com\"> support@platinumbiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 15, 2025\u003C\u002Fp>\u003Cp>CBER 25-705090\u003C\u002Fp>\u003Cp>Dear Mr. Russell:&nbsp;\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).&nbsp;\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.&nbsp;\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).&nbsp;\u003C\u002Fp>\u003Cp>Your Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.&nbsp;\u003C\u002Fp>\u003Cp>In addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.&nbsp;\u003C\u002Fp>\u003Cp>Your exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.&nbsp;\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.&nbsp;\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>Cc:&nbsp;\u003C\u002Fp>\u003Cp>Stephen Mesa\u003Cbr>Co-Founder\u003Cbr>Platinum Biologics, LLC\u003Cbr>1510 E. Colonial Drive, Suite 100\u003Cbr>Orlando, FL 32803\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&amp;C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 25-705090\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nBeeben Russell\n\nRecipient Title\n\nChairman of the Board\n\nPlatinum Biologics LLC\n\n1510 E Colonial Drive, Suite 103\n\nOrlando, FL 32803\n\nUnited States\n\nsupport@platinumbiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nAugust 15, 2025\nCBER 25-705090\nDear Mr. Russell:\nThe United States Food and Drug Administration (FDA) reviewed your company’s website at www.platinumbiologics.com\u002F (last visited August 2025), through which your company sells two umbilical cord derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use (collectively, “your products”).1 This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Your products are also unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under sections 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.platinumbiologics.com\u002F (last visited August 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your products are intended for use in the treatment of autoimmune disease, pain, depression, and the repair of age-related and trauma-related defects in connective tissue.\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Nano PRP Jelly and Nano Flex products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, your establishment does not qualify for any exception in 21 CFR 1271.15, and your products fail to meet all criteria in 21 CFR 1271.10(a).\nSpecifically, your Nano PRP Jelly and Nano Flex products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form and flowable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Nano PRP Jelly and Nano Flex products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor.” 21 CFR 1271.3(c) and 1271.10(a)(2). Your products are not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for healing, the repair of age-related and trauma related defects in connective tissue, shoulder injuries, and heart failure, which are not basic functions of umbilical cord tissue in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome products, NanoEx and Nano Xsomes are also drugs, as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as discussed above, and are subject to premarket review and approval requirements. We direct your attention to FDA’s public safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response and any questions regarding this letter to CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\nCc:\nStephen Mesa\nCo-Founder\nPlatinum Biologics, LLC\n1510 E. Colonial Drive, Suite 100\nOrlando, FL 32803\n__________________\n1 We note that you also market an umbilical cord derived product, Nano Flow, on your Facebook page, www.facebook.com\u002Fbeeben.russell\u002F. Umbilical cord derived products used to treat diseases and conditions in humans generally are regulated as drugs and biological products under the FD&C Act and the PHS Act, and as such, would be subject to all applicable requirements, including premarket review and current good manufacturing practice requirements. 21 CFR 1271.20.\n2 Because your Nano PRP Jelly and Nano Flex products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Platinum Biologics LLC","platinum-biologics-llc-705090-08152025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fplatinum-biologics-llc-705090-08152025","2026-10-26T08:09:42.645343+00:00","2025-08-26","705090","Beeben Russell","2026-08-19T16:29:05.979+00:00","Via UPS and EMAIL","CBER 25-705090","2025-08-15",{"id":144,"raw":145,"subject":65,"body_html":151,"body_text":152,"firm_name":153,"letter_id":154,"created_at":19,"fei_number":20,"letter_url":155,"updated_at":156,"action_type":23,"case_status":24,"posted_date":157,"marcs_cms_no":158,"product_type":76,"closeout_date":159,"issuing_office":160,"recipient_name":161,"body_fetched_at":162,"delivery_method":32,"recipient_title":20,"reference_number":163,"action_taken_date":164,"medical_device_id":20,"response_letter_date":20},1821,[146,147,148,149,64,13,150,13],"\u003Ctime datetime=\"2023-09-29T21:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-18T04:00:00Z\">09\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023\">Signature Biologics, LLC\u003C\u002Fa>"," Division of Biological Products Operations II","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-02212025\">\u003Ctime datetime=\"2025-03-06T05:00:00Z\">03\u002F06\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OBPO 23-631039\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Neil H. Riordan, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Signature Biologics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4040 W. Royal Lane, Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063-2844\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:neil@aidanresearch.com\"> neil@aidanresearch.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> #OBPO 23-631039\u003C\u002Fp>\n\n\u003Cp>September 18, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Riordan:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials per batch. However, from November 2018 through February 2020, your firm manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> commercial batches of Signature Cord™ with \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: \u003Cstrong>(b)(4)\u003C\u002Fstrong> colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for settling plate samples within the ISO 7 supporting cleanrooms, \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. \u003C\u002Fstrong>For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)].\u003C\u002Fstrong> For example, your firm failed to perform endotoxin testing as a release criterion on \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example, the manufacturing process for your product has not been validated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a two-year expiration date to your product without supporting data.\u003C\u002Fp>\n\n\u003Cp>FDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: Chloe R. Bailey, President and Chief Operating Officer\u003Cbr>\nSignature Biologics, LLC\u003Cbr>\n4040 W. Royal Lane, Suite 100\u003Cbr>\nIrving, TX 75063-2844\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup>, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that it discontinued their manufacture and distribution as of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is therefore FDA’s understanding that any previously manufactured Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature Matrix\u003Csup>TM\u003C\u002Fsup> and Signature MatrixHX\u003Csup>TM\u003C\u002Fsup> are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature Cord\u003Csup>TM\u003C\u002Fsup> appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOBPO 23-631039\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nNeil H. Riordan, Ph.D.\n\nRecipient Title\n\nChief Executive Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\nUnited States\n\nneil@aidanresearch.com\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWarning Letter #OBPO 23-631039\n\nSeptember 18, 2023\n\nDear Dr. Riordan:\n\nDuring an inspection of your firm, Signature Biologics, LLC, located at 4040 W. Royal Lane, Suite 100, Irving, TX 75063, conducted between December 1, 2021, and December 16, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of Signature Cord™, a product derived from human umbilical cord (“your product”) for allogeneic use.1 You have distributed Signature Cord™ directly to health care professionals and medical facilities for use in patients. Your product is intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during and\u002For after the inspection reflect that your product is intended to treat diseases or conditions. Additionally, information collected indicates that your product fits within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Therefore, your product is a drug as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological product as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nYour product is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Signature Biologics, LLC does not qualify for any exception in 21 CFR 1271.15, and Signature Cord™ fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, your product is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, Signature Cord™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because your processing alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement.2\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your product is not the subject of an approved biologics license application (BLA), nor is there an IND in effect for your product. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act [21 U.S.C. 351(a)(2)(B)] and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your product. FDA identified additional significant deviations upon further review of the information collected during the inspection, as discussed below. These CGMP deviations, involving over (b)(4) vials of your product manufactured and distributed between November 2018 and December 2021, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic processes used to manufacture your Signature Cord™ product in that the media fill batches used for your validation studies did not represent the maximum commercial batch size. For example, your validation studies entitled “Aseptic Processing Validation Report—Signature Cord” utilized a maximum of (b)(4) vials per batch. However, from November 2018 through February 2020, your firm manufactured (b)(4) commercial batches of Signature Cord™ with (b)(4) vials.\n\n2. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental monitoring in the aseptic processing areas where your products are manufactured. For example:\n\na. You have not performed microbiological monitoring of viable air in the ISO 7 supporting cleanrooms in association with each production run.\n\nb. Your environmental monitoring procedure describes the following as acceptable results for microbiological monitoring: (b)(4) colony forming units (CFUs) for surfaces within the ISO 7 supporting cleanrooms, (b)(4) CFUs for settling plate samples within the ISO 7 supporting cleanrooms, (b)(4) CFUs for personnel glove samples within the ISO 7 supporting cleanrooms, and (b)(4) CFUs for personnel garment samples within the ISO 7 supporting cleanrooms. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potentially significant safety concern.\n\n3. Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that the drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, at the time of the inspection, your finished product testing was limited to sterility testing as a measurement of product attributes.\n\n4. Each of batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements [21 CFR 211.167(a)]. For example, your firm failed to perform endotoxin testing as a release criterion on (b)(4) units of Signature Cord™ product manufactured and distributed by your firm since November 2018. By the nature of the route of administration, your product is purported to be pyrogen-free and is expected to be pyrogen-free.\n\n5. Failure to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example, the manufacturing process for your product has not been validated.\n\n6. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example, at the time of the inspection, you had not validated your process for cleaning and disinfecting the Biological Safety Cabinets (BSCs) and supporting cleanrooms where your product was manufactured.\n\n7. Failure to establish a written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a two-year expiration date to your product without supporting data.\n\nFDA received your written responses dated January 10, 2022, March 1, 2022, April 1, 2022, May 24, 2022, June 30, 2022, August 31, 2022, and November 2, 2022, to the inspectional observations on the Form FDA-483. The corrective actions described in your responses are not adequate to address the above-referenced deficiencies. We note that certain corrective actions cannot be evaluated because they lack supporting documentation. In addition, your responses do not address your specific plans for disposition of the inventory of Signature Cord™ at your facility. Additionally, for your previously distributed product, you do not describe actions you have taken or plan to take that adequately address the impact of the above-noted deficiencies on your distributed product that carries a two-year shelf life and was manufactured under the above-described conditions.\n\nWe acknowledge your commitment to voluntarily suspend the manufacture and distribution of Signature Cord™. However, your responses do not adequately address your failure to have an IND in effect to study your product addressed in this letter or your lack of an approved BLA to lawfully market your product. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the Form FDA-483, which were discussed with your firm at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response to this letter should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Products Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\nCc: Chloe R. Bailey, President and Chief Operating Officer\n\nSignature Biologics, LLC\n\n4040 W. Royal Lane, Suite 100\n\nIrving, TX 75063-2844\n\n_______________________\n\n1 During the December 2021 inspection, FDA also collected evidence that you have manufactured and marketed Signature MatrixTM and Signature MatrixHXTM, which are amniotic membrane derived products for allogeneic use. Your firm has represented that it ceased manufacturing these products in (b)(4) and that it discontinued their manufacture and distribution as of (b)(4). It is therefore FDA’s understanding that any previously manufactured Signature MatrixTM and Signature MatrixHXTM products are no longer within expiry. Based on information and records gathered prior to, during and\u002For after the inspection, Signature MatrixTM and Signature MatrixHXTM are intended to treat diseases or conditions in humans and are more than minimally manipulated. We note that these amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the “minimal manipulation” criterion at 21 CFR 1271.10(a)(1), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n2 We also note that based on the information and records gathered prior to, during and\u002For after the inspection, Signature CordTM appears to be intended to treat orthopedic diseases and conditions, for example. Such uses are not considered homologous use of umbilical cord. Signature CordTM must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the PHS Act and the regulations in 21 CFR Part 1271.","Signature Biologics, LLC","signature-biologics-llc-631039-09182023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsignature-biologics-llc-631039-09182023","2026-10-26T08:09:57.530976+00:00","2023-09-29","631039","2025-03-06","Division of Biological Products Operations II","Neil H. Riordan, Ph.D.","2026-08-20T00:38:15.637+00:00","OBPO 23-631039","2023-09-18",{"id":166,"raw":167,"subject":172,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":177,"fei_number":20,"letter_url":178,"updated_at":179,"action_type":23,"case_status":73,"posted_date":180,"marcs_cms_no":181,"product_type":182,"closeout_date":20,"issuing_office":171,"recipient_name":183,"body_fetched_at":184,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":185,"medical_device_id":20,"response_letter_date":20},2795,[168,169,170,171,172,13,13,13],"\u003Ctime datetime=\"2022-03-28T14:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-24T04:00:00Z\">03\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-biological-laboratories-inc-627062-03242022\">Applied Biological Laboratories Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael Latefi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Applied Biological Laboratories Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>760 Parkside Ave., 317\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11226\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mlatefi@appliedbioinc.com\"> mlatefi@appliedbioinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date: March 24, 2022\u003Cbr>\n\u003Cbr>\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biovanta.com and http:\u002F\u002Fwww.appliedbioinc.com in February and March 2022; the Federal Trade Commission (FTC) also reviewed these websites in March 2022. The FDA has observed that your website, https:\u002F\u002Fwww.biovanta.com, offers “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. We also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc where you direct consumers to your website, https:\u002F\u002Fwww.appliedbioinc.com, which directs consumers to https:\u002F\u002Fwww.biovanta.com to purchase your products. Based on our review, “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims, including on your websites, that establish the intended use of your products and misleadingly represents them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“In conclusion, the scientific studies demonstrate that the active ingredients in Biovanta help\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>reduce the inflammation that causes upper respiratory infections, including COVID-19, while leading brands, which are designed to mask symptoms, do more harm than good.” [from your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall\u002Fthe-science-behind-biovanta-cold-cough-and-sore-throatotc-medicine-scientifically-proven-safer-and-more-effective]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Applied Biological Laboratories… launched Biovanta… Biovanta is proven superior to other\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>leading products… in third-party, blind, placebo-controlled laboratory studies. The scientific\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>publication titled ‘Rational drug design for sore throat – An aspirin-based treatment that addresses\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>bradykinin-induced inflammation’ explains the studies in more detail. According to the publication,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Biovanta modulates cytokines and strengthens the respiratory lining. Key inflammatory molecules\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>studied include bradykinin, which is implicated in the cytokine storm associated with COVID-19 and\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>other serious upper respiratory diseases… Applied Biological Laboratories Inc. is a New York based\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>biotechnology company committed to the research, development, and manufacturing of\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>&nbsp;\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>drugs and therapies for respiratory diseases such as rhinovirus, influenza, coronavirus (including COVID-19), adenovirus, others.” [from the December 3, 2020 article as provided by you to PRNewswire,\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fbiovanta--the-only-100-natural-safeand-effective-over-the-counter-drug-for-cough-cold-and-sore-throat-301185288.html and to which you directly link from your May 20, 2021 post entitled “Biovanta: The only 100% natural, safe and effective over-the-counter drug for cough, cold and sore throat” on your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Just published the first scientific paper to finally address what works for sore throat, also to prevent a #BradykininStorm, treat #COVID_19 #COVID19 #SARSCoV2 symptoms and prevent #AntibioticResistance.” This is followed by a link to an abstract of your firm’s study entitled “Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin induced inflammation,” which mentions Biovanta. [from a November 8, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Despite my best efforts of trying to avoid getting sick during this pandemic, three days ago I got diagnosed with COVID 19. I had all the symptoms. I had a fever, I had a sore throat. My friend recommended me this product when told them that I was quarantining. It’s called Biovanta. It’s all natural. I got it from my local CVS and it’s a two step spray. I immediately noticed that it just like cleared my airways and I could take a deep breath.” [from a video called “Biovanta really helped me feel better!” you posted on your www.amazon.com Biovanta Throat Spray product page]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“More evidence that respiratory diseases should be treated in the nose and throat! https:\u002F\u002Flnkd.in\u002FdrSQX38N #biovanta #science #covid” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Study shows use of low-dose aspirin may prevent and shorten the duration of COVID-19 infection. More reasons to love our active ingredient. #science #covidー19 #innovation #health #aspirin #biovanta https:\u002F\u002Flnkd.in\u002Feu3bm23K” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Hey guys, so despite my best efforts of trying to avoid getting sick during this pandemic… by the time I came home I just started feeling really bad, tired, with a sore throat… noticed a dry cough and a sore throat… fever, I had a sore throat, I had a body aches and chills. I’m so excited that I found this product called Biovanta. It’s all natural which is awesome. I started seeing results immediately. And they deliver a really strong, really fast effective relief. The next day I felt 100%. The recovery was quick. It is phenomenal. Probably gonna get more of these and send them to my family and friends. I hope everyone stays safe out there and if anyone else is sick, I hope you feel better soon.” [from a video on your webpage https:\u002F\u002Fbiovanta.com\u002Fcollections\u002Fall-products and the YouTube video posted on December 18, 2020 on your Biovanta channel located at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=tIewyLf1EXo]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003Cstrong>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cstrong>FTC Cease and Desist Demand: \u003C\u002Fstrong>In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDonald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> According to the Cision PRNewswire Client Terms &amp; Conditions a “Client” purchases services from Cision and\u002For its affiliates and “[f]or each Release, Client shall indicate, in writing, (i) the name of the issuer of the Release. . . which name shall be displayed to the public as the source of the Release. . .” available at https:\u002F\u002Fwww.cision.com\u002Flegal\u002Fprnewswire-customer-terms-landing-page\u002F#info2.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Michael Latefi\n\nApplied Biological Laboratories Inc.\n\n760 Parkside Ave., 317\n\nBrooklyn, NY 11226\n\nUnited States\n\nmlatefi@appliedbioinc.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: March 24, 2022\n\nRE: Unapproved and Misbranded Product Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biovanta.com and http:\u002F\u002Fwww.appliedbioinc.com in February and March 2022; the Federal Trade Commission (FTC) also reviewed these websites in March 2022. The FDA has observed that your website, https:\u002F\u002Fwww.biovanta.com, offers “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. We also reviewed your social media websites at https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc where you direct consumers to your website, https:\u002F\u002Fwww.appliedbioinc.com, which directs consumers to https:\u002F\u002Fwww.biovanta.com to purchase your products. Based on our review, “Biovanta Dual Action Throat Spray” and “Biovanta Triple Action Lozenges” are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims, including on your websites, that establish the intended use of your products and misleadingly represents them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“In conclusion, the scientific studies demonstrate that the active ingredients in Biovanta help reduce the inflammation that causes upper respiratory infections, including COVID-19, while leading brands, which are designed to mask symptoms, do more harm than good.” [from your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall\u002Fthe-science-behind-biovanta-cold-cough-and-sore-throatotc-medicine-scientifically-proven-safer-and-more-effective]\n\n“Applied Biological Laboratories… launched Biovanta… Biovanta is proven superior to other leading products… in third-party, blind, placebo-controlled laboratory studies. The scientific publication titled ‘Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin-induced inflammation’ explains the studies in more detail. According to the publication, Biovanta modulates cytokines and strengthens the respiratory lining. Key inflammatory molecules studied include bradykinin, which is implicated in the cytokine storm associated with COVID-19 and other serious upper respiratory diseases… Applied Biological Laboratories Inc. is a New York based biotechnology company committed to the research, development, and manufacturing of drugs and therapies for respiratory diseases such as rhinovirus, influenza, coronavirus (including COVID-19), adenovirus, others.” [from the December 3, 2020 article as provided by you to PRNewswire,4 https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fbiovanta--the-only-100-natural-safeand-effective-over-the-counter-drug-for-cough-cold-and-sore-throat-301185288.html and to which you directly link from your May 20, 2021 post entitled “Biovanta: The only 100% natural, safe and effective over-the-counter drug for cough, cold and sore throat” on your webpage https:\u002F\u002Fbiovanta.com\u002Fblogs\u002Fall]\n\n“Just published the first scientific paper to finally address what works for sore throat, also to prevent a #BradykininStorm, treat #COVID_19 #COVID19 #SARSCoV2 symptoms and prevent #AntibioticResistance.” This is followed by a link to an abstract of your firm’s study entitled “Rational drug design for sore throat – An aspirin-based treatment that addresses bradykinin induced inflammation,” which mentions Biovanta. [from a November 8, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fappliedbiolabs]\n\n“Despite my best efforts of trying to avoid getting sick during this pandemic, three days ago I got diagnosed with COVID 19. I had all the symptoms. I had a fever, I had a sore throat. My friend recommended me this product when told them that I was quarantining. It’s called Biovanta. It’s all natural. I got it from my local CVS and it’s a two step spray. I immediately noticed that it just like cleared my airways and I could take a deep breath.” [from a video called “Biovanta really helped me feel better!” you posted on your www.amazon.com Biovanta Throat Spray product page]\n\n“More evidence that respiratory diseases should be treated in the nose and throat! https:\u002F\u002Flnkd.in\u002FdrSQX38N #biovanta #science #covid” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\n\n“Study shows use of low-dose aspirin may prevent and shorten the duration of COVID-19 infection. More reasons to love our active ingredient. #science #covidー19 #innovation #health #aspirin #biovanta https:\u002F\u002Flnkd.in\u002Feu3bm23K” [from a post on your social media webpage at https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fappliedbioinc]\n\n“Hey guys, so despite my best efforts of trying to avoid getting sick during this pandemic… by the time I came home I just started feeling really bad, tired, with a sore throat… noticed a dry cough and a sore throat… fever, I had a sore throat, I had a body aches and chills. I’m so excited that I found this product called Biovanta. It’s all natural which is awesome. I started seeing results immediately. And they deliver a really strong, really fast effective relief. The next day I felt 100%. The recovery was quick. It is phenomenal. Probably gonna get more of these and send them to my family and friends. I hope everyone stays safe out there and if anyone else is sick, I hope you feel better soon.” [from a video on your webpage https:\u002F\u002Fbiovanta.com\u002Fcollections\u002Fall-products and the YouTube video posted on December 18, 2020 on your Biovanta channel located at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=tIewyLf1EXo]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $46,517 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov certifying that you have ceased making unsubstantiated claims for the products identified above. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 According to the Cision PRNewswire Client Terms & Conditions a “Client” purchases services from Cision and\u002For its affiliates and “[f]or each Release, Client shall indicate, in writing, (i) the name of the issuer of the Release. . . which name shall be displayed to the public as the source of the Release. . .” available at https:\u002F\u002Fwww.cision.com\u002Flegal\u002Fprnewswire-customer-terms-landing-page\u002F#info2.","Applied Biological Laboratories Inc.","applied-biological-laboratories-inc-627062-03242022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-biological-laboratories-inc-627062-03242022","2026-10-26T08:07:56.783818+00:00","2022-03-28","627062","Drugs","Mr. Michael Latefi","2026-08-20T02:04:41.098+00:00","2022-03-24",8,{"510k":188,"classification":189,"enforcement":190,"event":191,"event_backfill":192,"pma":193,"warning_letter":194},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]